Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses. Results: Thirty-six trials involving 18 889 patients using triple regimens (NK-1RAþserotonin receptor antagonists [5HT3RA] þ dexamethasone) or duplex regimen (5HT3RAþdexamethasone) to control CINV were included in the analysis. Different NK-1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR] duplex/triple ¼ 0.47-0.66). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (OR duplex/triple ¼ 0.52, 95% confidence interval [CI] ¼ 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs. Conclusions: Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.
commonly dexamethasone, were first used for the treatment of CINV in the early 1990s (4) . Thereafter, the addition of serotonin receptor antagonists (5HT3RAs) showed additional improvement in acute CINV, which act via peripheral nervous pathways of gastrointestinal tracts (5) . Furthermore, recent studies found that dexamethasone plus 5HT3RA and neurokinin-1 receptor antagonists (NK-1RAs) made greater advances in controlling CINV because NK-1RA could play a role in both acute and delayed CINV through blocking the actions of substance P (SP) in the vomiting center of the brain (5) . As a result, combination antiemetic therapy is the standard regimen for patients receiving HEC or MEC to prevent CINV (6) (7) (8) . Recent clinical practice guidelines recommend a 5HT3RA plus an NK-1RA and a corticosteroid for HEC, and a 5HT3RA plus a corticosteroid, with or without an NK-1 RA, for MEC (6) (7) (8) .
Because there are various NK-1RAs (aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant) and 5HT3RAs (first generation: ondansetron and granisetron; second generation: palonosetron) for oncologists to choose from, according to sufficient clinical data, a large-scale analysis is needed to answer whether the efficacy and toxicity of antiemesis are different among those NK-1RA-based triple antiemetic regimens. Besides, it is still unclear whether the antiemetic efficacy in palonosetron-based triple regimens is better compared with first-generation 5HT3RAs-based triple regimens. Moreover, whether the doses of dexamethasone in combination with NK-1RA plus 5HT3RA will impact the antiemetic effect is also unknown. Therefore, a network meta-analysis is an optimal method to compare different regimens because of its good agreement in the real-world situation (9, 10) .
Methods

Search Strategy and Selection Criteria
We systematically searched the PubMed, Embase, and Cochrane Central Register of Controlled Trials databases using a combination of the terms "neurokinin-1 receptor antagonist," "aprepitant," "casopitant," "fosaprepitant," "netupitant," and "rolapitant" to find relevant articles published up to February 2016. A manual search through reference lists of relevant reviews was additionally performed. Three authors carried out the literature retrieval independently (YZ, YY, ZZ). Eligible studies met the following criteria: 1) they were randomized control trials (RCTs) or prospective studies that evaluated NK-1RA-based triple antiemetic regimens in the prophylaxis of CINV; 2) efficacy and/or toxicity measures were available; 3) NK-1RA was used at the standard dose. Studies failing to meet these inclusion criteria were excluded.
Outcomes Measures, Data Extraction,and Quality Assessment
The outcomes of antiemetic efficacy were the proportions of patients with complete responses (CRs) and no clinically significant nausea in the acute (0-24 hours after chemotherapy), delayed (>24-120 hours after chemotherapy), and overall (0-120 hours) phases. The toxic outcome was defined as treatment-related adverse events (TRAEs). The assessment of efficacy and toxicity occurred during the first cycle of chemotherapy.
The data on trial name, therapeutic and antiemetic regimens, and clinical outcomes were extracted by two investigators independently (YZ and ZZ). HEC, such as anthracycline plus cyclophosphamide (AC) or cisplatin, and MEC, such as carboplatin or oxaliplatin, were defined according to the National Comprehensive Cancer Network Antiemesis Guideline Version 2, 2016 (11) . Cochrane risk of bias was used to assess the quality of all included studies by another two reviewers (YL and YY) (12) . Discrepancies were discussed by all investigators to reach a consensus. More details on this can be found in Supplementary  Figure 1 (available online).
Statistical Analyses
First, we conducted pair-wise meta-analyses using a randomeffects model to synthesize studies comparing the same pair of antiemetic treatments. The results were reported as pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Statistical heterogeneity across studies was assessed with a forest plot and the inconsistency statistic (I 2 ). Statistical significance was set at a P value of .05. All calculations were (13, 14) . Secondly, a random-effects network within a Bayesian framework using the Markov chain Monte Carlo methods was built using ADDIS 1.15 (15, 16) . We networked binary clinical outcomes within studies and specified the relations among the ORs across studies to make comparisons of different antiemetic treatments in terms of efficacy and/or toxicity. P values of less than .05 and 95% confidence intervals were used to assess statistical significance. The inconsistency within this multiple treatment comparison was evaluated by a variance calculation as previously described (16) . All statistical tests were two-sided.
Results
Eligible Studies and Population Characteristics
We identified 1796 records using the search strategy and included 35 studies (17-51), including 36 trials involving 18 889 cancer patients using NK-1RA-based triple antiemetic regimens (NK-1RAþ5HT3RAþdexamethasone, n ¼ 12 051) or conventional duplex control regimen (5HT3RAþ dexamethasone, n ¼ 6838) to control for CINV in this meta-analysis. Figure 1 shows the flow chart for the study selection procedure. There were 21, 11, and four trials that used HEC (17) (18) (19) (20) (21) (22) (23) (26) (27) (28) (29) 31, 32, 34, 36, 38, 39, 45, 46, 49) , MEC (24, 33, 35, (40) (41) (42) (43) (44) 48, 50, 51) , and mixed chemotherapy regimens (25, 30, 37, 47) , respectively. Table 1 and Supplementary  Table 1 (available online) give more detailed characteristics of all the studies included in our analyses.
Pair-Wise Meta-Analyses for Antiemetic Efficacy and Toxicity
NK-1RAs-based triple regimens showed statistically significantly superior antiemetic effect in overall, acute, and delayed phase CRs compared with conventional duplex regimens in overall patients, patients with HEC, and patients with MEC (Table 2) . Similar results were found when "no clinically significant nausea" was the toxicity investigated (Supplementary  Table 2 , available online). However, no statistically significant difference of TRAE was found between NK-1RA-based triple regimens and duplex control regimen (Table 2) . We used funnel plots to assess the publication bias of the literature in this study. All the shapes of the funnels were close to symmetric, and no publication bias was found according to Begg's test and Egger's test (P > .05).
Networks for Multiple Treatment Comparisons
Network A was designed for multiple treatment comparison of different NK-1RA-based triple antiemetic regimens (NK1RAþ5HT3RAþdexamethasone) and the conventional duplex control regimen (5HT3RAþdexamethasone) (Figure 2A ). Network B established the comparison of palonosetron-based triple regimen (NK-1RAþpalonosetronþdexamethasone) and first-generation 5HT3RAs-based triple regimen (NK-1RAþ1st generation 5HT3RAsþdexamethasone) through duplex regimens (palonosetronþdexamethasone and first-generation 5HT3RAsþdexamethasone) ( Figure 2B ). In addition, network C was built for multiple treatment comparison of NK-1RA-based triple antiemetic regimens and conventional duplex control regimens with various doses of dexamethasone ( Figure 2C ).
Network Meta-Analyses for Antiemetic Efficacy and Toxicity
According to the data based on network A, various NK-1RAs-based triple regimens (aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant) shared equivalent antiemetic effect in overall, acute, and delayed phase CRs without statistically significant differences in odds ratios. In all patients and patients with HEC, almost all NK-1RAs-based triple regimens showed statistically significantly higher CRs in all phases vs duplex control regimen (OR duplex/triple ¼ 0.47-0.66), while only netupitantbased triple regimen had a statistically nonsignificant superior antiemetic efficacy compared with duplex control regimen in terms of acute phase CR. However, in patients with MEC, only aprepitant-based triple regimen showed a statistically significantly better antiemetic effect than duplex control regimen in all outcome measures of efficacy (OR duplex/triple ¼ 0.52, 95% CI ¼ 0.34 to 0.68). We observed no statistically significant difference in the antiemetic effect of TRAE among different NK-1RA-based triple regimens vs the duplex control regimen (Table 3) .
Subgroup Analyses and Consistency Evaluation
According to the data based on network B, the antiemetic efficacy of palonosetron-based triple regimens was similar to firstgeneration 5HT3RAs-based triple regimens for CRs in all phases. Moreover, different doses of dexamethasone in combination with NK-1RA plus 5HT3RA showed no statistically significant difference in terms of CRs in all phases (Table 4 ). All the network meta-analyses in our study were used in both the consistency model and the inconsistency model. The variances of those two models were roughly equal. As a result, inconsistency did not appear to be present, and we used the consistency model to show our results.
Discussion
To our knowledge, this is the first meta-analysis to compare the antiemesis efficacy among various NK-1RAs-based triple regimens. Our study showed that different NK-1RAs-based triple regimens had an equivalent effect on CINV control in the overall, acute, and delayed phases after chemotherapy. Almost all the NK-1RAs-based triple regimens showed statistically significant higher CRs in all phases compared with duplex control regimen in patients with HEC. However, only aprepitant-based triple regimen provided statistically significantly better CINV prevention vs duplex control regimen in patients receiving MEC. Our study also found that palonosetron and first-generation 5HT3RAs had similar effectiveness for CINV control in all phases when used with NK-1RAs. Moreover, there was no difference between different doses of dexamethasone in the prevention of CINV in all phases when combined with NK-1RAs and 5HT3RAs. Consistent with the results of individual RCTs, our study confirmed that NK1RAs-based triple regimen had higher efficacy of CINV control than duplex control regimen in patients receiving HEC. As expected, we also found that various NK-1RAs-based triple regimens showed a similar effect on CINV control in all phases. Thus any NK-1RAs-based triple regimen could be used for patients receiving HEC. To date, guidelines only recommend NK1RAs-based triple regimens for patients who receive HEC or anthracycline-cyclophosphamide treatment. Our study demonstrated that patients who receive MEC could also derive clinically significant benefit from applying NK-1RAs-based triple regimens that are of a similar magnitude as patients receiving HEC. Our findings suggest the application of NK-1RAs-based triple regimens for patients receiving MEC. However, subgroup analyses indicated that only aprepitant, rather than other NK1RAs, was associated with statistically significantly increased CINV control compared with duplex control regimen in patients receiving MEC. Therefore, aprepitant might be the preferred choice when applying triple regimens to patients receiving MEC.
Palonosetron is a second-generation 5-HT3 receptor antagonist with higher binding affinity against 5-HT3 receptor and longer half-time than first-generation 5-HT3 receptor antagonists (granisetron, dolasetron, and ondansetron) (52, 53) . The high affinity and long half-life of palonosetron might explain its better antiemetic effect throughout the delayed emesis risk period compared with first-generation 5-HT3 receptor antagonists. Several large randomized phase III studies and meta-analyses assessed the effectiveness of palonosetron compared with first-generation 5-HT3 receptor antagonists in controlling vomiting emesis induced by both HEC and MEC. These studies demonstrated that palonosetron was superior to first-generation 5-HT3 receptor antagonists in preventing CINV in both the delayed phase and overall phase Table 3 . Odds ratios and 95% confidence intervals for antiemetic efficacy and toxicity measured as complete response and treatment-related ARTICLE (54) (55) (56) (57) . However, in these studies, palonosetron or first-generation 5-HT3 receptor antagonists were used without the presence of NK-1RAs. Thus it is still unclear if palonosetron would be more effective than first-generation 5-HT3 receptor antagonists in CINV control when NK-1RAs were used. Our study found that palonosetron and first-generation 5HT3RAs showed an equivalent effect on CINV control in all phases in the presence of NK-1RAs.
ARTICLE
Therefore, because of its higher cost, palonosetron may not be recommended as the preferred 5-HT3 receptor antagonist. Further clinical trials comparing the effectiveness of palonosetron and first-generation 5HT3RAs when combined with NK-1RAs are warranted to verify our findings.
Because of a lack of other effective antiemetics, high doses of dexamethasone were used to improve CINV control.
Delayed phase CR (HEC), No. of trials ¼ 19 (17, (19) (20) (21) (22) (23) (27) (28) (29) 31, 32, 34, 36, 38, 39, 45, 46, 49) 
According to a meta-analysis of 32 studies published from 1966 to 1999, the mean total dose of dexamethasone was 56 mg (58) . A high dose of dexamethasone was associated with several side effects, such as hypertension, hyperglycemia, and insomnia. However, there was no strong evidence to support the relationship between the higher dose of dexamethasone and better efficacy in CINV control (59, 60) . In addition, several NK-1RAs such as aprepitant, fosaprepitant, and netupitant were CYP3A4 inhibitors. Thus the dose of dexamethasone should be decreased when used with these NK-1RAs because of CYP3A4 inhibition. Moreover, data from clinical trials suggested that in combination with NK-1RAs and 5HT3RAs, low dose of dexamethasone also showed clear efficacy (31, 36, 39) . Therefore, the optimal dose of dexamethasone in NK-1RAs-based triple regimens remains unknown. According to our study, there was no difference between different doses of dexamethasone in the prevention of CINV in all phases when combined with NK-1RAs and 5HT3RAs. To minimize the adverse events related to dexamethasone, a lower dose of dexamethasone might be used with NK-1RAs and 5HT3RAs. However, dose-finding studies for dexamethasone should be conducted in combination with NK-1RAs and 5HT3RAs to confirm these findings.
Olanzapine is an atypical antipsychotic drug that blocks multiple neuronal receptors involved in the nausea and vomiting pathways (61) . It has been studied for CINV control, especially in patients presenting with nausea and vomiting refractory to standard antiemetics (61) . A previous study showed that olanzapine had similar antiemetic effect compared with aprepitant in patients with HEC in combination with dexamethasone and 5HT3RAs (62) . Recently, a single-arm trial reported that preventive use of olanzapine combined with triplet therapy (NK-1RA, 5HT3RA, and dexamethasone) showed better antiemetic effect than those from previously reported studies of triplet therapy (63) . However, our study did not cover the evidence of olanzapine in CINV control because of limited data, which was not enough for multiple treatment comparisons. Future analyses are warranted to compare olanzapine-based regimens with NK-1RAs-based regimens in CINV control.
According to our results, we found that the odds ratios for both the delayed phase and overall phase appeared to be very similar in most end points. It seemed that the overall phase results didn't add substantially to the current knowledge. Acute and delayed phase results might represent all of the useful information from this analysis. Further research about whether ARTICLE the overall phase result should be excluded in future study design, statistical analysis, and regulatory review is needed. Our study is not without limitations. First, the lack of connections in the networks made the results dependent on only a few studies so that some of the presented estimates were based exclusively on indirect evidence. Second, we were not able to extract specific patients' data on HEC or MEC in some of the included studies that enrolled mixed patients. Third, we could not compare netupitant-based triple regimen and rolapitant-based triple regimen with other NK-1RAs-based triple regimens. Future studies were warranted to confirm our results.
Despite the above limitations, our study confirmed that different NK-1RAs-based triple regimens were associated with an equivalent effect on CINV control in all the phases. Various NK1RAs-based triple regimens had superior antiemetic effect than duplex control regimen in patients with HEC. Only aprepitantbased triple regimen showed better CINV control compared with duplex control regimen in patients receiving MEC. Moreover, palonosetron and first-generation 5HT3RAs might share equivalent effect on CINV control in the combination of NK-1RAs and dexamethasone. A lower dose of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.
